How should a clinical trial be designed to compare early video‑assisted thoracoscopic surgery versus conventional tube thoracostomy (and intrapleural fibrinolytic therapy) in adult patients with confirmed thoracic empyema, including appropriate inclusion and exclusion criteria, interventions, and outcome measures?

Clinical Trial Design: Early VATS vs. Tube Thoracostomy with Fibrinolytics for Thoracic Empyema

Based on current evidence, a clinical trial comparing early VATS to conventional tube thoracostomy with intrapleural fibrinolytic therapy should NOT be designed to test early VATS as first-line treatment, as the 2023 British Thoracic Society guidelines explicitly state that early surgical drainage should not be considered over chest tube drainage for initial treatment of pleural infection. 1

Trial Design Framework

Population (Inclusion Criteria)

Primary Inclusion:

• Adults ≥18 years with confirmed thoracic empyema (stage II or III)
• Pleural fluid pH ≤7.2 OR
• Pleural fluid glucose <3.3 mmol/L OR
• Pleural fluid LDH >900 IU/L with clinical parameters supporting complicated parapneumonic effusion (ongoing fever, high pleural fluid volume, septations on ultrasound, pleural enhancement on CT) 1
• Community-acquired pleural infection
• Multiloculated effusion confirmed on thoracic ultrasound
• Failed initial small-bore chest tube drainage (≤14F) for 48-72 hours with persistent collection

Key Exclusion Criteria:

• Malignant pleural effusion
• Traumatic or iatrogenic empyema
• History of pleurodesis or tuberculosis 2
• Contraindications to surgery or fibrinolytic therapy
• Bleeding diathesis or therapeutic anticoagulation that cannot be temporarily ceased 1
• Pregnancy

Intervention Arms

Arm 1: Tube Thoracostomy + Intrapleural Fibrinolytic Therapy

• Small-bore chest tube (≤14F) placement under ultrasound guidance 1
• Combination TPA + DNase regimen: 10 mg TPA twice daily + 5 mg DNase twice daily for 3 days (or lower dose 5 mg TPA twice daily + 5 mg DNase twice daily if higher bleeding risk) 1
• NOT streptokinase (increases complications with no mortality benefit) 1
• Continue antibiotics per institutional protocol

Arm 2: Video-Assisted Thoracoscopic Surgery (VATS)

• VATS debridement/decortication as appropriate for empyema stage
• Disruption of pleural septations, drainage of purulent fluid, irrigation
• Complete decortication only if lung trapped and patient fit for procedure 1
• Small-bore chest tube placement post-operatively
• Continue antibiotics per institutional protocol

Primary Outcome Measures (Prioritizing Morbidity, Mortality, QOL)

Primary Outcome:

• Length of hospital stay after intervention (most consistently reported outcome with demonstrated differences) 3

Co-Primary Outcomes for Comprehensive Assessment:

• 30-day mortality (critical for patient safety)
• Treatment failure rate requiring additional intervention (surgery after fibrinolytics, or repeat surgery after VATS)

Secondary Outcome Measures

Morbidity Indicators:

• Total length of hospital stay from admission 1
• ICU admission rate and duration 4
• Duration of fever post-intervention 5, 3
• Duration of chest tube drainage 5, 6
• Postoperative complications (wound infection, persistent pleural space, recurrent infection, bleeding) 1, 7, 4
• Need for repeat intervention or conversion to open thoracotomy 1

Quality of Life Measures:

• Pain scores (postoperative and at 12 months) - critical as surgery patients report more residual chest pain 2
• Dyspnea duration 6
• Analgesic requirements 6, 8
• Quality of life questionnaires at 3,6, and 12 months
• Return to normal activities timeline

Radiographic Outcomes:

• Lung re-expansion at discharge and 2-week follow-up 9
• Chest X-ray abnormalities at follow-up 8

Sample Size Considerations

Based on existing RCT data 3, with median hospital stay differences of 2 days (4 vs 2 days), power calculation should target:

• Minimum 90-100 patients per arm to detect clinically meaningful differences in length of stay
• Account for 10-15% dropout rate
• Total enrollment target: 200-220 patients

Randomization Strategy

• Stratified randomization by:
  • Empyema stage (II vs III)
  • RAPID score (low 0-2, medium 3-4, high 5-7) - validated predictor of mortality and outcomes 1
  • Presence of septations on ultrasound (complex septated vs non-septated)

Critical Design Considerations

Timing of Intervention:

• Both arms should receive intervention within 24-48 hours of failed initial chest tube drainage
• Define "failure" as: persistent fever >48 hours, inadequate drainage (<50% reduction in effusion size), or worsening clinical status

Standardization Requirements:

• All VATS procedures performed by experienced thoracic surgeons (>20 VATS empyema cases/year)
• Standardized fibrinolytic protocol with no deviation
• Uniform antibiotic protocols across sites
• Blinded outcome assessment for radiographic endpoints

Safety Monitoring:

• Data Safety Monitoring Board review at 25%, 50%, 75% enrollment
• Pre-specified stopping rules for excess mortality or complications in either arm

Follow-Up Schedule

• Daily until hospital discharge
• 2 weeks post-discharge (clinical + imaging)
• 1,3,6, and 12 months (clinical + QOL assessments)
• Chest imaging at 2 weeks and 3 months minimum

Evidence-Based Rationale

The 2023 BTS guidelines provide a conditional recommendation against early surgical drainage as initial treatment 1, but acknowledge that VATS "appears to reduce the need for repeat intervention and length of hospital stay when compared with standard chest tube drainage" 1. However, this evidence is graded as "Ungraded" due to lack of high-quality RCTs.

When surgery IS indicated (after failed medical management), VATS demonstrates clear superiority over thoracotomy with 2.3 days shorter hospital stay, fewer complications (152 vs 197 per 1000 patients), less postoperative pain, and slightly lower mortality (35 vs 47 per 1000) 1.

Recent studies show conflicting results: one 2020 RCT found early medical thoracoscopy shortened post-intervention stay compared to fibrinolytics (2 vs 4 days, p=0.026) 3, while pediatric data increasingly favor VATS 6, 8. The ongoing FIVERVATS trial 10 will provide crucial comparative data, but results are pending.

Critical caveat: The trial must acknowledge that current guideline-concordant care is initial small-bore chest tube drainage, with escalation to either fibrinolytics or surgery based on response. Testing early VATS as first-line contradicts current evidence-based recommendations and requires robust ethical justification and informed consent processes.